PatientsVille.com Logo

PRODUCT USE ISSUE and Abilify

PatientsVille

PRODUCT USE ISSUE Symptoms and Causes

The products you use for cleaning, carpentry, auto repair, gardening, and many other household uses can contain ingredients that can harm you, your family, and the environment. These include

  • Oven and drain cleaners
  • Laundry powder
  • Floor polish
  • Paint thinners, strippers and removers
  • Pesticides
  • Grease and rust removers
  • Motor oil and fuel additives
  • Arts and craft supplies

Toxic substances in these products can cause harm if inhaled, swallowed, or absorbed through the skin. People respond to toxic substances in different ways. At high doses a toxic substance might cause birth defects or other serious problems, including brain damage or death.

To avoid problems, keep products in the containers they come in and use them exactly as the label says. Follow label directions or get medical help if you swallow, inhale or get them on your skin.

Environmental Protection Agency

Check out the latest treatments for PRODUCT USE ISSUE

PRODUCT USE ISSUE treatment research studies

Abilify clinical trials, surveys and public health registries


Find Drug Side Effect reports



Abilify Side Effects

Weight Increased (761)
Tremor (544)
Tardive Dyskinesia (527)
Insomnia (486)
Pregnancy (435)
Dyskinesia (400)
Dizziness (324)
Somnolence (323)
Nausea (313)
Restlessness (308)
Headache (296)
Fatigue (289)
Psychotic Disorder (287)
Akathisia (286)
Anxiety (281)
Agitation (257)
Vomiting (254)
Convulsion (243)
Delusion (233)
Blood Glucose Increased (228)
Depression (192)
Dystonia (189)
Feeling Abnormal (188)
Vision Blurred (185)
Suicidal Ideation (179)
Death (178)
Mania (178)
Hallucination (176)
Aggression (174)
Neuroleptic Malignant Syndrome (169)
Fall (169)
Confusional State (167)
Weight Decreased (150)
Extrapyramidal Disorder (140)
Dyspnoea (136)
Hallucination, Auditory (136)
Schizophrenia (135)
Gait Disturbance (135)
Abnormal Behaviour (135)
Muscle Spasms (133)
Suicide Attempt (131)
Loss Of Consciousness (128)
Hyperhidrosis (125)
Musculoskeletal Stiffness (123)
Dysphagia (123)
Asthenia (121)
Blood Creatine Phosphokinase Increased (110)
Oedema Peripheral (109)
Completed Suicide (108)
Irritability (105)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

dystonia...on the right hand

Abilify for BiPolar Disorder, how does it work for you?

Abilify lifts the cloud of depression for me But - the sweating is profuse -- just dripping if I do any kind of movement

Abilify, lost everything, could'nt stop gambling until I got off of it.

Abilify, side effects ruined my life. I have compulsive bahavior, I gambled I lost everything. I am looking for a good Lawyer. (409) 548-0460.

As human experience is limited, administration of aripiprazole should be used in pregnancy only if the potential benefit to the mother outweighs the potential risk to the foetus.

Can it cause constipation? My lil was had been bad

Can't sleep any more than 3 to 4 hours at a time anyone else with that problem?

Developed bruxism after starting abilify and lithium

Did not know what was going on, panic attacks yesterday. muscle cramping and tremor, sleeplessness, its all here, going off of this. very scary

i never had an issue with using theraflu before. this time around i feel drunk every time i take it. i feel really super drowsy. and it is not working at all. i am still very congested even though i have a runny nose. i am still sore all over even t

>:o Took my first dose today,it left me covered in a red itchy rash on neck,chest,back and sides within 10 minutes of consuming.This product is now sitting in the trash can. :(

Hey Michelle, we almost have the same issue..I switched from Yaz to Trinessa because I and my husband thought it caused my severe mood swings prior to my period. I have been running and working out but I start experiencing joint

<span style='color: #808080;'><b>Describe Your Nystagmus from DTAP + IPV + HIB (PENTACEL) 2010 Experience Here: My duagters very first set of vaccination shots at 3 months caused nystagmus. We did not notice the issue

'OCAS' means that the product is administered over a time period. For this reason it must be swallowed whole and not chewed.

....however, dalacine is very effective unto face. kaya ngaun patuloy na ang paggamit ko sa product na ito.. try niyo rin para masubukan niyo. sabi nga hindi mo malalaman ang tamis hangat hindi mo nasusubukan ang pa.it....jejejeje' &nb

1.2-methyl-2-butene is treated with the following reagents write the structural formula of the mian organic product in each case

According to unspsc classification ,in which commodity this product fall?

After i use sensordyne , i have extremely pain travel from the back of my throat and uperjaw to my head . I though this product will reduce sensitivity in my teeth , now i have more pain then before.

After one day, extreme fatigue and swelling in the ankles. This drug is poison and should be pulled. No warranty or return on product by manufacturer.

PRODUCT USE ISSUE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Aripiprazole 6-week group;   Drug: Aripiprazole 8-week group
Outcome Measures: Quality of Life Scale (QOLS);   Montgomery-Åsberg Depression Rating Scale
2 Unknown  Aripiprazole and Topiramate on Free-Choice Alcohol Use
Condition: Alcohol Dependence
Interventions: Drug: Double Placebo;   Drug: Aripiprazole 15, placebo;   Drug: Aripiprazole 7.5, Placebo;   Drug: Topiramate 100, Placebo;   Drug: Topiramate 200, Placebo;   Drug: Topiramate 100, Aripiprazole 15;   Drug: Topiramate 100, Aripiprazole 7.5;   Drug: Topiramate 100, Aripiprazole 15mg;   Drug: Topiramate 200, Aripiprazole 7.5mg;   Drug: Topiramate 200, Aripiprazole 15
Outcome Measures: Number of alcoholic drinks consumed in a laboratory setting;   Safety and tolerability of the medications singly and in combination, compared to placebo;   Drinks consumed during the medication titration period
3 Recruiting Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia
Condition: Hyperprolactinemia
Interventions: Drug: Aripiprazole;   Drug: Placebo
Outcome Measures: To determine if adjunct aripiprazole will resolve or improve prolactin related hormonal side effects (amenorrhea, oligomenorrhea, galactorrhea).;   To test whether adjunctive aripiprazole will improve quality/perceived quality of life.;   To identify if adjunct aripiprazole will improve bone turnover as measured by assays of osteoblastic and osteoclastic activity.;   To examine side effects associated with adjunctive aripiprazole versus placebo and conduct a cost analysis of adjunctive aripiprazole use.;   To evaluate the mediator effects of estrogen, progesterone, prolactin effects on quality of life, bone turnover and sexual functioning.
4 Unknown  The New Strategy for Pharmacological Treatment in People With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Rispridoen and Aripiprazole;   Drug: Risperidne;   Drug: Abilify
Outcome Measures: SANS(Scale for the Assessment of Negative Symptoms);   SARS(Simpson-Angus Rating Scale);   Drug Attitude Inventory;   Side effect checklist
5 Recruiting Study to Evaluate the Efficacy and Safety of Aripiprazole
Condition: Autism
Intervention: Drug: Aripiprazole
Outcome Measures: irritability subscale of the aberrant behavior checklist;   Change from baseline in ABC-subscale of lethargy/social withdrawal, stereotypic behavior, hyperactivity, inappropriate speech;   Change of CGI-S, CGI-I from baseline;   Change of Behavioral problems from baseline;   Change of Adaptive Skills from baseline;   Change of Parental stress from baseline
6 Recruiting Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
Condition: Bipolar I Disorder
Interventions: Drug: Intramuscular (IM) Depot Aripiprazole;   Drug: Intramuscular (IM) Depot Placebo
Outcome Measures: Time from randomization to recurrence of any mood episode during Double-Bind Placebo Controlled phase;   Proportion of subjects meeting criteria for recurrence of any mood episode(manic, mixed, depressive);   Mean change from randomization to endpoint in the CGI-BP-S (mania) score;   Time from randomization to recurrence defined by hospitalization for a mood episode.
7 Unknown  Neuroimaging Of Treatment Effects in Treatment-Resistant Depression
Condition: Major Depressive Disorder
Intervention: Drug: escitalopram and adjunctive aripiprazole and placebo
Outcome Measures: Use of PET and fMRI to demonstrate the differential pattern of dopaminergic activity, dopamine receptor binding in the putamen and caudate and correlation these findings to MADRS in MDD subjects treated with escitalopram and aripiprazole.;   Correlation of D2binding before and after adjunctive aripiprazole with emergence of extrapyramidal symptoms and akathisia.
8 Recruiting Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Aripiprazole and aripiprazole once-monthly;   Drug: Paliperidone and paliperidone palmitate
Outcome Measures: Mean change from Baseline in quality of life;   Investigator's assessment of overall effectiveness;   Mean change from Baseline in clinical global impression;   Mean change from Baseline in quality of life using QLS;   Mean change from Baseline in subjective well-being using SWN-S;   Mean change from Baseline in tolerability and quality of life using TooL;   Safety and tolerability;   Risk of suicidality
9 Recruiting Aripiprazole and Prolactin Study
Condition: Hyperprolactinemia
Intervention: Drug: Aripiprazole
Outcome Measures: Normalization or reduction in prolactin sufficient to restore gonadal function;   Normalization or improvement in bone mineral density
10 Recruiting A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole
Outcome Measures: Adverse events;   Positive and Negative Syndrome Scale (PANSS);   Clinical golobal impression (CGI);   Children's Global Assessment Scale (CGAS)
11 Unknown  Aripiprazole Augmentation Therapy in Treatment-resistant Depression
Condition: Therapy-resistant Depression
Intervention: Drug: Aripiprazole
Outcome Measure: rate of response as defined by a more or equal 50 % reduction of baseline HAM-D (Hamilton Depression Rating scale)
12 Recruiting Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole
Outcome Measures: Prolactin level;   PANSS (positive and negative syndrome scale) score
13 Recruiting A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Aripiprazole Low (2 mg/day);   Drug: Aripiprazole Mid (6 - 12 mg/day);   Drug: Aripiprazole High (24 - 30 mg/day)
Outcome Measures: Positive and Negative Syndrome Scale (PANSS) total sore;   PANSS score;   Clinical Global Impression (CGI);   Children's Global Assessment Scale (CGAS);   Adverse events;   Electrocardiogram
14 Unknown  Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole
Conditions: Schizophrenia;   Sensory Gating
Intervention: Drug: Aripiprzole
Outcome Measure: MEG/EEG and MRI data will be compared with the results of a neuropsych battery and symptom rating scales prior to initiation with aripiprazole and after subject has been on a stable dose of aripiprazole for three month.
15 Unknown  Aripiprazole and Resistant Postpartum Depression
Condition: Postpartum Depression
Intervention: Drug: aripiprazole
Outcome Measures: Montgomery Asberg Depression Rating Scale;   Udvalg for Kliniske Undersogelser Scale
16 Recruiting Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
Condition: Bipolar I
Intervention: Drug: Aripiprazole
Outcome Measures: Number and percentage of subjects with adverse events;   Injection Site Pain measured by the Visual Analog Scale (VAS);   Number and percentage of subjects with clinically significant abnormal laboratory test results, vitals, ECGs;   Extrapyramidal Symptoms (EPS) will be assessed by change from baseline on Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS used in Japan), and Barnes Akathisia Rating Scale (BARS);   Percentage of subjects who remain stable at endpoint
17 Unknown  Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
Condition: Autistic Disorder
Interventions: Drug: Aripiprazole;   Drug: Placebo;   Drug: D-cycloserine;   Other: fMRI
Outcome Measures: Aberrant Behavior Checklist (ABC) Irritability Subscale;   Clinical Global Impression (CGI) Scale;   ABC Subscales;   Vineland Maladaptive Behavior Subscales;   A modified version of the Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS);   Autism Diagnostic Observation Schedule (ADOS);   Social Reciprocity Scale (SRS)
18 Recruiting Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
Condition: Autistic Disorder
Interventions: Drug: Aripiprazole;   Drug: Risperidone
Outcome Measure: To identify phenotypic and genetic traits that predict response to aripiprazole and risperidone in Autistic Disorder
19 Recruiting Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study
Conditions: Bipolar Disorder;   Depressive Episode
Interventions: Drug: Low dose Adjunctive Aripiprazole;   Drug: placebo
Outcome Measure: Response rate
20 Recruiting A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
Conditions: Schizophrenia;   Cocaine Dependence
Interventions: Drug: Aripiprazole;   Drug: Perphenazine
Outcome Measures: The proportion of negative urine drug screen results will be significantly greater in the subjects treated with aripiprazole than in those treated with perphenazine.;   The mean total self-report cocaine use days will be significantly fewer in subjects treated with aripiprazole than in those treated with perphenazine.;   The mean cocaine craving scores will be lower in subjects treated with aripiprazole than in those treated with perphenazine.